Switzerland's cannabis pilot trials

TL;DR

• Legal basis: BetmPV of May 2021, in force since 15 May 2021.
• Duration: up to 10 years of scientifically supervised studies.
• First study: Weed Care Basel (launched 30 Jan 2023).
• Goal: gather evidence for a future regulated-market reform.

Cities and studies

Basel (Weed Care), Zurich (Züri Can), Bern (SCRIPT), Geneva, Lausanne, Biel and Lucerne test different models — pharmacy dispensing, associations, social clubs. All studies are approved by the FOPH and evaluated by universities (UZH, Basel, Bern).

Regulatory framework and legal scope

The implementation of the scientific pilot trials is based on a targeted amendment to the Narcotics Act (BetmG). With the corresponding article in the BetmG, the Federal Council has created the legal basis to test the controlled sale of cannabis for recreational purposes within a limited timeframe and geographical area. While a strict ban applies outside of these trials to THC-containing cannabis with more than 1% total THC, participants within the research projects benefit from a legally protected framework. The Federal Office of Public Health (FOPH) monitors compliance with the strict requirements and ensures that distribution takes place exclusively through licensed points of sale.

A central aspect of the legal regulation concerns product safety and the protection of minors. The products distributed within the framework of the trials must meet strict quality standards, which are supported by the Federal Food Safety and Veterinary Office (FSVO) and Swissmedic. The protection of minors is ensured by strictly excluding minors from participation. Furthermore, the strict zero-tolerance practice on Swiss roads remains unaffected. Anyone caught at the wheel with a THC level of over 1.5 micrograms per litre of blood continues to be deemed unfit to drive, regardless of the legal origin of the cannabis consumed from the pilot projects.

• Legal safeguarding through the experimental clause in the Narcotics Act (BetmG).
• Strict quality controls of the products offered regarding contaminants and THC content.
• Unchanged validity of the strict limits for unfitness to drive in road traffic.
• Exclusive distribution to registered trial participants to prevent black market trade.

Scientific objectives and study designs

The Swiss pilot trials are primarily designed as health-economic and social-scientific research projects. The participating universities systematically investigate how regulated access affects consumption behavior, the physical and mental health of participants, and the illegal market. By comparing different distribution models, such as sales in pharmacies or organization in non-profit cannabis social clubs, the researchers want to find out which form of distribution offers the greatest social acceptance and the best protection of minors. The data obtained will serve as a scientific basis for decision-making in future national legislation.

Another focus of the accompanying research is on prevention and harm reduction. Since, unlike on the black market, the products have declared ingredients and controlled THC concentrations, it is possible to investigate whether consumers are transitioning to lower-risk forms of consumption. The staff at the points of sale are specially trained to intervene early in the event of signs of abuse and to provide counseling services. In the event of suspected medical emergencies or overdoses, the expertise of Tox Info Suisse is also available to ensure seamless support and scientific documentation of adverse effects throughout the duration of the study.

• Researching the effects of legal distribution on the illegal cannabis black market.
• Comparing the effectiveness of pharmacy distribution and cooperatively organized social clubs.
• Focus on harm reduction through trained staff and on-site education.
• Scientific monitoring to record health and social changes.

Regional differences and cantonal implementation

Switzerland's federalist structure is also reflected in the concrete implementation of the various pilot projects. While urban centres like Zurich and Basel were able to establish comprehensive studies with various points of sale relatively quickly, other regions are proceeding more cautiously. The cantonal authorities have considerable leeway in enforcing the Narcotics Act, which leads to different priorities. Some cantons focus heavily on social integration and the role of associations, while others want to restrict dispensing strictly to medically supervised channels in order to maximize health supervision.

Social acceptance and the political debate also vary greatly from region to region. In French-speaking Switzerland, socio-educational approaches and harm reduction are often at the forefront, while in German-speaking Switzerland, regulatory and economic issues are more frequently discussed. Regardless of regional differences, however, all projects must comply with strict federal requirements. This includes the obligation to prevent the misuse of study documents. Anyone caught with cannabis outside the defined study area or without a valid ID must expect regular administrative fines or criminal consequences, depending on the canton.

• Federalist differences in the enforcement and design of local studies.
• Different priorities between social association models and medical pharmacies.
• Regional debates on the social impact of controlled sales.
• Strict compliance with national requirements despite cantonal autonomy in enforcement.

FAQ